Tessera Therapeutics
Tessera develops Gene Writing and RNA delivery technologies for genomic changes and targeted in vivo applications. Its November 2026 ASH announcement concerns preclinical studies, including CAR-T generation in nonhuman primates.
Corporate information
- Company entity
- Tessera Therapeutics
- Headquarters / principal office
- Somerville, MASelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 2018 ↗
- Ownership / capital status
- Not verifiedVerified historical Series C; not a guarantee of the latest round ↗
- Official corporate reference
- https://www.tesseratherapeutics.com/gene-writing ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2022-04-20 · Series C (historical disclosure) · More than $300 million ↗
Uses transaction counsel announcement date; historical financing is not a current valuation. Gates Foundation funding and Regeneron collaboration payments are not added.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Tessera develops Gene Writing and RNA delivery technologies for genomic changes and targeted in vivo applications. Its November 2026 ASH announcement concerns preclinical studies, including CAR-T generation in nonhuman primates.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Tessera Therapeutics | Gene Writing™
- Tessera — corporate history and 2026 pipeline update
- Tessera Series C — transaction counsel confirmation
- Company-managed LinkedIn profile — self-reported location